Literature DB >> 8565887

Highly flexible self-expanding meshed metal stents for palliation of malignant esophagogastric obstruction.

K E Grund1, D Storek, H D Becker.   

Abstract

BACKGROUND AND STUDY AIMS: Palliative treatment methods for esophageal and cardiac cancer include dilation, laser vaporization and other thermal methods, alcohol injection, and stent insertion. None of these procedures, however, has proved to be a simple, well-tolerated, and lasting method. We present here our results with a new, highly flexible self-expanding metal stent made of nitinol, which is considered to be particularly useful for difficult (long and tortuous) malignant strictures. PATIENTS AND METHODS: From November 1991 to December 1994, 114 patients with unresectable esophagogastric malignancies or tumor recurrences (92 men, 22 women, mean age 64 years) were treated using 138 highly flexible meshed self-expanding metal stents. Regular clinical and endoscopic follow-up was performed, and stent obstruction or overgrowth was treated by argon plasma coagulation (APC). Patients were followed up until death (n = 78; average follow-up 17 weeks, range 1-90 weeks). Thirty-six patients were alive in December 1994 and had had an average of 20 weeks of follow-up (range 1-160 weeks).
RESULTS: Stent insertion was technically successful in 97% of cases, and led to a reduction of dysphagia (graded 0-4) from a mean score of 3.5 to a mean score of 1.5. Preparatory treatment to open tight strictures was necessary in 80% of cases. Balloon dilation to support stent expansion was carried out in 42 patients (37%). During follow-up, tumor ingrowth occurred in 66% of cases after a mean of seven weeks, and was successfully treated by APC. Including preparatory treatment and re-treatment, patients underwent a mean of 3.5 endoscopic procedures (range 1-12 procedures), which led to good clinical success in 73% of cases. Ninety-six percent of the patients continued to be able to swallow (dysphagia score < or = 2) during follow-up.
CONCLUSIONS: Highly elastic self-expanding metal stents can be successfully implanted in the majority of patients, particularly in those with difficult malignant strictures not easily amenable to other methods. The devices provide good palliation with effective relief of dysphagia, easy handling and implantation, and offer a satisfactory quality of life to the patient. However, tumor ingrowth is a significant problem, even though it can be successfully managed by APC. Adequate covering of the stent that does not affect its mechanical properties or firm anchoring should solve at least some of these problems.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8565887     DOI: 10.1055/s-2007-1005753

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  6 in total

1.  Guidelines for the management of oesophageal and gastric cancer.

Authors:  W H Allum; S M Griffin; A Watson; D Colin-Jones
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

2.  Covered stenting in patients with lifting of gastric and high esophago-tracheal fistula.

Authors:  T Lehnert; J O Balzer; M Sachs; C Herzog; T J Vogl
Journal:  Eur Radiol       Date:  2003-03-08       Impact factor: 5.315

Review 3.  [1997 gastroenterology update--II].

Authors:  W Fischbach; V Gross; J Schölmerich; C Ell; P Layer; W E Fleig
Journal:  Med Klin (Munich)       Date:  1998-03-15

4.  Laser and brachytherapy in the palliation of adenocarcinoma of the oesophagus and cardia.

Authors:  G M Spencer; S M Thorpe; I R Sargeant; G M Blackman; J Solano; J S Tobias; S G Bown
Journal:  Gut       Date:  1996-11       Impact factor: 23.059

5.  [Stenoses and fistula in the high cervical esophagus: part I: therapy and stent implantation].

Authors:  K E Grund; J Gräter
Journal:  HNO       Date:  2010-04       Impact factor: 1.284

Review 6.  Esophageal stent fracture: case report and review of the literature.

Authors:  Harshit S Khara; David L Diehl; Seth A Gross
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.